- US finalizes up to $6.6 bn funding for chip giant TSMC
- Scholz urges Ukraine talks in first call with Putin since 2022
- Zverev reaches ATP Finals last four, Alcaraz on brink of exit
- Lebanon rescuer picks up 'pieces' of father after Israel strike
- US retail sales lose steam in October after hurricanes
- Zverev reaches ATP Finals last four with set win against Alcaraz
- Kerevi back for Australia against Wales, Suaalii on bench
- Spate of child poisoning deaths sparks S.Africa xenophobia
- Comedian Conan O'Brien to host Oscars
- Rozner overtakes McIlroy and Hatton for Dubai lead
- Mourners bid farewell to medic killed in east Ukraine
- Gore says 'absurd' to hold UN climate talks in petrostates
- Hamas says 'ready for ceasefire' as Israel presses Gaza campaign
- Amorim says Man Utd is 'where I'm supposed to be'
- Japan hammer Indonesia to edge closer to World Cup spot
- Jeff Beck guitar collection to go under the hammer in January
- Veteran Ranieri has 'no time for mistakes' on Roma return
- Van Nistelrooy says he will 'cherish' Man Utd memories in farewell message
- IAEA chief tours sensitive Iran nuclear plants
- Pompeii rejects 'mass tourism' with daily visitor limit
- Jailed Russian poet could be 'killed' in prison, warns wife
- French court orders release of Lebanese militant held since 1984
- Global stocks struggle after Fed signals slower rate cuts
- UK economy slows, hitting government growth plans
- Primary schools empty as smog persists in Indian capital
- Palestinians turn to local soda in boycott of Israel-linked goods
- Typhoon Man-yi bears down on Philippines still reeling from Usagi
- UK growth slows in third quarter, dealing blow to Labour government
- Chris Wood hits quickfire double in NZ World Cup qualifying romp
- Markets struggle at end of tough week
- China tests building Moon base with lunar soil bricks
- Film's 'search for Palestine' takes centre stage at Cairo festival
- Oil execs work COP29 as NGOs slam lobbyist presence
- Gore says climate progress 'won't slow much' because of Trump
- 'Megaquake' warning hits Japan's growth
- Stiff business: Berlin startup will freeze your corpse for monthly fee
- Wars, looming Trump reign set to dominate G20 summit
- Xi, Biden attend Asia-Pacific summit, prepare to meet
- Kyrgios to make competitive return at Brisbane next month after injuries
- Dominican Juan Luis Guerra triumphs at 25th annual Latin Grammys
- Landslide win for Sri Lanka president's leftist coalition in snap polls
- Australian World Cup penalty hero Vine takes mental health break
- As Philippines picks up from Usagi, a fresh storm bears down
- Tropical Storm Sara pounds Honduras with heavy rain
- Pepi gives Pochettino win for USA in Jamaica
- 'Hell to heaven' as China reignite World Cup hopes with late winner
- Rebel attacks keep Indian-run Kashmir on the boil
- New Zealand challenge 'immense but fantastic' for France
- Under pressure England boss Borthwick in Springboks' spotlight
- All Blacks plan to nullify 'freakish' Dupont, says Lienert-Brown
RBGPF | 2.67% | 61.84 | $ | |
CMSC | 0.04% | 24.56 | $ | |
RYCEF | 0.88% | 6.85 | $ | |
RELX | -3.43% | 44.425 | $ | |
NGG | 0.19% | 62.49 | $ | |
BTI | 1.57% | 36.055 | $ | |
AZN | -2.34% | 63.55 | $ | |
BP | -0.14% | 29.009 | $ | |
RIO | 0.71% | 60.86 | $ | |
SCS | 0.26% | 13.305 | $ | |
GSK | -2.53% | 33.1605 | $ | |
CMSD | 0.17% | 24.4 | $ | |
VOD | 0.69% | 8.74 | $ | |
BCE | -1.11% | 26.545 | $ | |
BCC | 0% | 140.355 | $ | |
JRI | -0.38% | 13.0266 | $ |
US panel weighs authorizing Covid vaccines for youngest children
After months of anxious wait for some parents, a panel of experts convened by the US Food and Drug Administration will meet Wednesday to weigh recommending Covid vaccines for the nation's youngest children.
Children under five are the only age group not yet eligible for Covid immunization in the United States and most other countries. If, as expected, panelists vote in favor of greenlighting the Pfizer and Moderna vaccines, formal authorizations should follow quickly, with the first shots in arms expected by next week.
Ahead of the meeting, the FDA posted its independent analyses of the two drugs, deeming both safe and effective. It also said there was a pressing unmet need to inoculate children in the age group since their rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age."
Both vaccines are based on messenger RNA technology, which delivers genetic code for the coronavirus spike protein to human cells, training the immune system to be ready for when it encounters the real virus.
Pfizer is seeking authorization for three doses at three micrograms given to ages six months through four years, while Moderna has asked for the FDA to approve its vaccine as two doses of a higher 30 micrograms, for ages six months through five years.
They were tested in trials of thousands of children where they were found to have similar levels of mild effects to older age groups and triggered similar levels of antibodies.
Efficacy against infection was higher for Pfizer, with the company placing it at 80 percent compared to Moderna's estimates of 51 percent in the six-month-old to age two group and 37 percent in the two to five years age group.
But the figures are provisional and Moderna is studying adding a third dose later that may increase its figures.
There are some 20 million US children aged four years and under. If the FDA-appointed experts recommend the two vaccines, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said the rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
Of the total US Covid deaths, 480 have come in children under five, according to the latest official data.
Obesity, neurological disorders and asthma are associated with increased risk of severe disease, "however, a majority of children hospitalized for Covid-19 have no underlying medical conditions," the FDA said in a document.
Children can also go on to contract multisystem inflammatory syndrome in children (MIS-C), a rare but serious post-viral condition.
Data on long Covid in children is sparse, but the FDA's document cited a national survey in the United Kingdom which found that "among children ages two to 11 years who tested positive for COVID-19, 7.2 percent reported continued symptoms at 12 weeks."
D.Johnson--AT